Immediate Impact
1 by Nobel laureates 2 from Science/Nature 60 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Works of See‐Chun Phan being referenced
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).
2018
Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| See‐Chun Phan | 297 | 247 | 89 | 17 | 427 | |
| Annett Maderer | 245 | 157 | 92 | 24 | 424 | |
| Katia Dotti | 350 | 145 | 87 | 28 | 490 | |
| Anghel Adrian Udrea | 255 | 221 | 96 | 15 | 383 | |
| Qiuxia Dong | 314 | 191 | 127 | 14 | 495 | |
| Jie Huang | 276 | 236 | 158 | 25 | 468 | |
| Edith Rodríguez-Braun | 327 | 152 | 154 | 21 | 471 | |
| Domenico Germano | 178 | 120 | 138 | 22 | 403 | |
| Carlo Barone | 203 | 193 | 65 | 20 | 381 | |
| Marta Caporale | 248 | 144 | 112 | 16 | 415 | |
| Jan Kuhlmann | 181 | 127 | 119 | 19 | 427 |
All Works
Loading papers...